Navigation Links
Global Cystic Fibrosis Heat Map and Analysis 2016-2022 - Research and Markets
Date:1/13/2017

DUBLIN, Jan 13, 2017 /PRNewswire/ --

Research and Markets has announced the addition of the "Cystic Fibrosis - Heat Map and Analysis" report to their offering.

Cystic fibrosis (CF) is a progressive genetic condition and is the result of a patient inheriting a faulty cystic fibroses transmembrane conductance regulator (CFTR) gene from both parents. The defective CFTR genes produce faulty CFTR proteins on the body's epithelial cells, and result in the buildup of a thick and sticky mucus in the lungs and pancreas.

Historically therapeutic options have focused heavily on treating the symptoms, but despite being clinically and commercially successful have failed to address the faulty CFTR proteins that cause the disease. This unmet need has led to the development of CFTR modulators.

The treatment algorithm patients receive is likely to consist of an antimicrobial, a mucolytic agent, pancreatic enzymes and possibly a CFTR modulator. This tabular heatmap framework, designed to provide an easily digestible summary of these clinical characteristics, provides detailed information on all late-stage clinical trial results for products in the CF market and Phase III or Preregistration stages of the pipeline. These are split along drug class lines, and are therefore reflective of the treatment algorithm.

All safety and efficacy endpoints reported in these trials are displayed. In addition, key study characteristics such as the size, composition and patient segment of the study population are provided. These results are presented in a visually accessible, color-coded manner in order to maximize ease of use.

The accompanying text provides a detailed analysis of the clinical benchmarks set by the current market landscape, and the anticipated changes to these benchmarks, and to the treatment algorithm, as a result of the late-stage pipeline.

Scope

- To what extent is the CF market landscape expected to change with the introduction of new CFTR modulators?
- What are the clinical characteristics of currently approved therapies for CF, in terms of specific safety and efficacy parameters?
- What are the key unmet needs in this indication, and which clinical safety and efficacy parameters are the most closely linked to them?
- How will current late-stage CFTR modulators affect the market for symptomatic therapies, and are they able to yield comparable clinical efficacy results to Kalydeco?
- How will the influx of tobramycin generics affect the competitive landscape?

Key Topics Covered:

1. Table of Contents

2. Introduction
2.1 Report Guidance

3. Marketed Products
3.1 Antimicrobeals
3.2 Mucolytic Agents
3.3 Pancreatic Enzymes
3.4 CFTR modulators

4. Pipeline Products
4.1 Changes to Antimicrobeals, 2016-2022
4.2 Changes to Mucolytic Agents, 2016-2022
4.3 Changes to Pancretic Enzymes, 2016-2022
4.4 Changes to CFTR Modulators, 2016-2022

5. Appendix

For more information about this report visit http://www.researchandmarkets.com/research/cslw9m/cystic_fibrosis

Media Contact:

Laura Wood, Senior Manager
press@researchandmarkets.com 

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-cystic-fibrosis-heat-map-and-analysis-2016-2022---research-and-markets-300390730.html


'/>"/>
SOURCE Research and Markets
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Global Information Online Market Research Portal Provides Complimentary Sample Service for Customers to Preview Reports by Global Industry Analysts
2. Cumberland Pharmaceuticals To Present At The UBS Global Healthcare Conference In New York
3. The Rockley Group and Content Rules Ink Deal to Extend Global Reach
4. AcelRx Pharmaceuticals to Present at the UBS Global Healthcare Conference
5. Amgen To Present At The UBS Global Life Sciences Conference
6. HeartWare Presentation At The 2013 UBS Global Healthcare Conference To Be Webcast
7. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the 2013 UBS Global Healthcare Conference in New York City
8. PENTAX Medical And Hitachi-Aloka Medical Continue Joint Innovation And Global Leadership In Endoscopic Ultrasound Systems
9. Orexigen Therapeutics to Present at the UBS Global Healthcare Conference
10. TRACE Releases 2012 Global Enforcement Report
11. Valeant Pharmaceuticals To Present At 34th Annual Goldman Sachs Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/11/2018)... (PRWEB) , ... August 10, 2018 , ... Dry eye ... Some of these products are excellent, and they do provide some relief from dry ... use than a product created and marketed by a small company in tiny Grants ...
(Date:8/11/2018)... SAN FRANCISCO (PRWEB) , ... August 11, 2018 ... ... Left Handers Day on Monday, August 13, with fun, games and gifts. Left-Handers ... in a world designed for right-handers. Having endured centuries of prejudice, countless indignities ...
(Date:8/9/2018)... ... 2018 , ... Autism is a developmental disorder affecting more than 3.5 million ... 1 in 68 people have the disorder), chances are you know someone on the ... child with autism methods of communication and tactics to interact with others. These options ...
Breaking Medicine Technology:
(Date:8/3/2018)... ... August 03, 2018 , ... Firstaid4sport ... Gerry Newlove first started the Firstaid4sport business in the 1990's and his son ... one of the leading providers in the UK of sports medicine products, supplying ...
(Date:8/3/2018)... ... August 03, 2018 , ... Lucyd Pte Ltd, ... announce the launch of its online store. The Lucyd eShop will feature the ... innovations in spectacles. , The eShop will have a number of unique ...
(Date:8/2/2018)... Calif. (PRWEB) , ... August 02, 2018 , ... ... be featuring its premium Resona 7 Ultrasound system with unique new upgrades at ... San Antonio, Texas. Based on ZONE Sonography® Technology (ZST), the upgrades include a ...
(Date:8/2/2018)... ... August 02, 2018 , ... A new ... topics in acute pain management. In The Role of Acute Care in the ... Engagement Network—an innovative approach to the opioid epidemic launched in the state of ...
(Date:8/2/2018)... ... ... Continuing their momentum in 2018 Sempulse has been selected as one of ... Ecliptic Capital, Mike W. Erwin, an early investor in Sempulse is bullish on the ... over 30 years starting companies and investing locally. The ideas, innovation and funding coming ...
Breaking Medicine News(10 mins):